Skip to main content

Super navigation

  • Newsroom
    • The Latest
    • Press releases
    • argenx Stories
    • Downloadable assets
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
Home
Global websites
  • Global: English
Local websites
  • Germany: Deutsch
  • Japan: 日本語
  • Netherlands: Nederlands
  • Spain: Español
  • United Kingdom: English

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us

Breadcrumb

  1. Home
  2. Press Releases

Press Releases

  • (-) Any
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
Reset

2021

September 2, 2021
argenx to Present at Upcoming Investor Conferences
August 25, 2021
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
August 4, 2021
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
July 29, 2021
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
July 22, 2021
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
July 14, 2021
argenx to Host Virtual R&D Day on July 20, 2021
June 16, 2021
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
June 7, 2021
argenx to regain global rights to cusatuzumab
June 1, 2021
argenx Appoints Karl Gubitz as Chief Financial Officer
June 1, 2021
argenx to Present at Upcoming Investor Conferences
May 14, 2021
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
May 11, 2021
argenx announces results of Annual General Meeting of Shareholders

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • MyRealWorld MG
    • Clinical trials
    • Patient access
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
    • Publications
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Products
  • Investors
    • Stock information
    • Events & Presentations
    • Financial reports
    • Shareholder meetings
    • Corporate governance
    • AFM filings
    • SEC filings
    • Analyst coverage
  • Careers
    • Dare to do more
    • Join argenx
    • Benefits
    • Employee stories
  • Newsroom
    • The Latest
    • argenx stories
    • Press releases
    • Downloadable assets
  • About
    • One Team
    • Values
    • Management Team
    • Board of Directors
    • Grants
    • Ethics and Responsibility
    • Contact us
2023 © argenx
Disclaimer
Privacy policy
Regulations